English
-
31 Jul, 2023
Spago Nanomedical interim report January-June 2023
-
28 Jun, 2023
Spago Nanomedical updates on the clinical phase IIa study SPAGOPIX-02
-
13 Jun, 2023
Spago Nanomedical strengthens Tumorad® by establishment of Scientific Advisory Board
-
23 May, 2023
Spago Nanomedical has submitted application to start Tumorad® clinical phase I/IIa study
-
10 May, 2023
Bulletin from the 2023 Annual General Meeting of Spago Nanomedical AB
-
9 May, 2023
Spago Nanomedical interim report January-March 2023
-
4 May, 2023
Presentation of Spago Nanomedical’s clinical phase IIa study in endometriosis at the 15th World Congress of Endometriosis
-
5 Apr, 2023
Notice to Annual General Meeting of Spago Nanomedical AB (publ)
-
4 Apr, 2023
The nomination committee proposes changes to the board of Spago Nanomedical for increased commercial focus
-
29 Mar, 2023
Spago Nanomedical publishes the annual report for 2022